More recently, significantly elevated serum HHV-6 IgM in MS patients versus controls was reported in an Iranian population [31], and a positive, dose-dependent correlation of serum HHV-6 IgG titers with MS relapse risk was reported in an Australian MS cohort [32]. Here, CD40LG is linked to myeloid sarcoma.